Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 5:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 97 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Moderately to Severely Active Crohn's Disease Clear all
Completed Phase 3 Interventional

A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease

NCT00078611
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
63
States / cities
Oro Valley, Arizona • Tucson, Arizona • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease

NCT02394028
View directory record Official record
Conditions
Crohn Disease
Interventions
Etrolizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
62
States / cities
Arcadia, California • La Jolla, California • Long Beach, California + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

NCT00552344
View directory record Official record
Conditions
Crohn Disease
Interventions
Cimzia
Biological
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
20
States / cities
Lakewood, Colorado • Littleton, Colorado • New Port Richey, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 10, 2026, 5:20 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy

NCT05470985
View directory record Official record
Conditions
Crohn Disease
Interventions
Ozanimod
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
2 Years to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Garden Grove, California • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 10, 2026, 5:20 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

NCT06063967
View directory record Official record
Conditions
Crohn's Disease
Interventions
Risankizumab SC, Placebo for risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
79
States / cities
Sun City, Arizona • Corona, California • Coronado, California + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 10, 2026, 5:20 PM EDT
Recruiting Phase 3 Interventional

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

NCT07499232
View directory record Official record
Conditions
Crohn Disease
Interventions
Guselkumab, Risankizumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
39
States / cities
Dothan, Alabama • Mobile, Alabama • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 10, 2026, 5:20 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819891
View directory record Official record
Conditions
Moderately to Severely Active Crohns Disease
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years to 80 Years
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
61
States / cities
Dothan, Alabama • Glendale, Arizona • Lancaster, California + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

NCT00552058
View directory record Official record
Conditions
Crohn Disease
Interventions
certolizumab pegol (CDP870, CZP), Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
24
States / cities
Pell City, Alabama • Colorado Springs, Colorado • Lakewood, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

NCT01369329
View directory record Official record
Conditions
Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
Interventions
Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg, Group 1: Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
67
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

NCT02531113
View directory record Official record
Conditions
Crohn's Disease
Interventions
RPC1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
Tucson, Arizona • Largo, Florida • Palmetto Bay, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)

NCT02611817
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab SC 108 mg, Placebo, Vedolizumab IV 300 mg
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
Phoenix, Arizona • Hamden, Connecticut • Middletown, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 10, 2026, 5:20 PM EDT
Recruiting Phase 3 Interventional

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931
View directory record Official record
Conditions
Crohn's Disease
Interventions
Duvakitug, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years to 80 Years
Enrollment
980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
125
States / cities
Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 105 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 10, 2026, 5:20 PM EDT
Recruiting Phase 4 Interventional

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

NCT06581328
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab IV, Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

NCT03345849
View directory record Official record
Conditions
Crohn's Disease
Interventions
Upadacitinib, Placebo for Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
119
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 10, 2026, 5:20 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease

NCT07298421
View directory record Official record
Conditions
Moderately to Severely Active Crohns Disease
Interventions
Afimkibart
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 10, 2026, 5:20 PM EDT
Not yet recruiting Phase 2 Interventional

A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease

NCT07677514
View directory record Official record
Conditions
Crohn's Disease
Interventions
H021 Enteric-coated Tablets Low-dose Group, H021 Enteric-coated Tablets High-dose Group, Placebo Group
Drug
Lead sponsor
Jiangsu Carephar Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Hamden, Connecticut • Lighthouse PT, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 10, 2026, 5:20 PM EDT
Active, not recruiting No phase listed Observational

A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

NCT02130362
View directory record Official record
Conditions
Crohn's Disease
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
45
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

NCT03104413
View directory record Official record
Conditions
Crohn's Disease
Interventions
placebo for risankizumab IV, risankizumab SC, risankizumab IV
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
114
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 10, 2026, 5:20 PM EDT
Recruiting Phase 2 Interventional

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

NCT06233461
View directory record Official record
Conditions
Crohn's Disease
Interventions
TAK-279, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
30
States / cities
Murrieta, California • Orange, California • Clearwater, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

NCT03105128
View directory record Official record
Conditions
Crohn's Disease
Interventions
placebo for risankizumab, risankizumab IV, risankizumab SC
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
931 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
117
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

NCT02914561
View directory record Official record
Conditions
Crohn's Disease
Interventions
Filgotinib, Placebo
Drug · Other
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
101
States / cities
Dothan, Alabama • Sun City, Arizona • Coronado, California + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 10, 2026, 5:20 PM EDT
Active, not recruiting Phase 2 Interventional

Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

NCT05910528
View directory record Official record
Conditions
Crohns Disease
Interventions
Afimkibart
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Dothan, Alabama • Hamden, Connecticut • Kissimmee, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 10, 2026, 5:20 PM EDT
Terminated Not applicable Interventional Results available

NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease

NCT00936585
View directory record Official record
Conditions
Colitis, Crohn's Disease, Inflammatory Bowel Disease
Interventions
Immunologic Monitoring
Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 10, 2026, 5:20 PM EDT
Completed Phase 2 Interventional

CP-461 for the Treatment of Crohn's Disease

NCT00042055
View directory record Official record
Conditions
Crohn's Disease
Interventions
CP-461
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2011 · Synced Oct 10, 2026, 5:20 PM EDT